BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11533610)

  • 1. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition.
    Porter KE; Dickinson T; London NJ
    J Vasc Surg; 2001 Sep; 34(3):548-54. PubMed ID: 11533610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
    Raoch V; Martinez-Miguel P; Arribas-Gomez I; Rodriguez-Puyol M; Rodriguez-Puyol D; Lopez-Ongil S
    Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
    J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
    Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.
    Seed A; Kuc RE; Maguire JJ; Hillier C; Johnston F; Essers H; de Voogd HJ; McMurray J; Davenport AP
    Life Sci; 2012 Oct; 91(13-14):743-8. PubMed ID: 22480515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
    Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle.
    Maguire JJ; Johnson CM; Mockridge JW; Davenport AP
    Br J Pharmacol; 1997 Dec; 122(8):1647-54. PubMed ID: 9422810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Jeng AY; Savage P; Beil ME; Bruseo CW; Hoyer D; Fink CA; Trapani AJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
    J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
    Grantham JA; Schirger JA; Wennberg PW; Sandberg S; Heublein DM; Subkowski T; Burnett JC
    Circulation; 2000 Apr; 101(16):1976-81. PubMed ID: 10779465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
    Usmani BA; Harden B; Maitland NJ; Turner AJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():314S-317S. PubMed ID: 12193112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL; Winardi W; Jeng AY; Kwan AL
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice.
    De Campo BA; Goldie RG; Jeng AY; Henry PJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():353S-356S. PubMed ID: 12193121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
    De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
    J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
    Mulder P; Barbier S; Monteil C; Jeng AY; Henry JP; Renet S; Thuillez C
    J Cardiovasc Pharmacol; 2004 Apr; 43(4):489-94. PubMed ID: 15085059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
    Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
    Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B; Daull P; Jeng AY
    Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.